CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Mepolizumabbiological
Likely dose
Mepolizumab 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00527566
NCT00527566Phase 2Completed
CompareCT.gov

Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome

Brigham and Women's Hospital·interventional·Posted Sep 11, 2007·Updated Mar 22, 2017

In Brief

A Phase 2 clinical trial evaluating Mepolizumab for Churg Strauss Syndrome. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Mepolizumab (a monoclonal antibody against interleukin-5) is a safe and well-tolerated therapy that will allow for steroid tapering in patients with steroid-dependent Churg-Strauss Syndrome (CSS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChurg Strauss Syndrome
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 11, 2007
Enrollment StartSep 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.8 years ago

Interventions

Mepolizumabbiological

IV mepolizumab, 750 mg